Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphomafor Lymphoplasmacytic LymphomaDrug: Venetoclax136 locations incl. TucsonSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT04840602·Phase 2·RecruitingApply to this trial